NRx Pharmaceuticals Inc. (NRXP)
NASDAQ: NRXP
· Real-Time Price · USD
2.86
0.19 (7.12%)
At close: Aug 15, 2025, 3:40 PM
7.12% (1D)
Bid | 2.83 |
Market Cap | 55.83M |
Revenue (ttm) | 4K |
Net Income (ttm) | -24.11M |
EPS (ttm) | -1.96 |
PE Ratio (ttm) | -1.46 |
Forward PE | 3.15 |
Analyst | Buy |
Ask | 2.93 |
Volume | 532,736 |
Avg. Volume (20D) | 275,080 |
Open | 2.76 |
Previous Close | 2.67 |
Day's Range | 2.60 - 2.95 |
52-Week Range | 1.10 - 6.01 |
Beta | 1.60 |
About NRXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NRXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NRXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+24.56%
NRx Pharmaceuticals shares are trading higher afte...
Unlock content with
Pro Subscription
7 months ago
+30.48%
NRX Pharmaceuticals shares are trading higher after the company announced it will acquire Dura Medical with HOPE Therapeutics. Additionally, the company signed a binding term sheet with HOPE with $27 million to fund further acquisitions and pharmaceutical operations.

2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Makes New Investment in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchang...

3 months ago · seekingalpha.com
NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call TranscriptNRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Matthew Duffy – Chief Business Officer Jonathan Javitt – Founder, Chairman, and C...